Reprogramming of pericytes in fibrosis
Pericyte reprogramming in fibrosis
This study is looking at how certain cells around blood vessels, called pericytes, change into another type of cell that helps cause scarring in tissues, which can lead to fibrosis, and the goal is to find new ways to treat this condition for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10896140 on NIH RePORTER |
What this research studies
This research investigates how pericytes, which are specialized cells associated with blood vessels, contribute to the development of fibrosis, a condition characterized by excessive tissue scarring. The study focuses on understanding the transition of pericytes into myofibroblasts, which are cells that play a significant role in tissue remodeling and fibrosis progression. By exploring the mechanisms behind this cellular change, the research aims to uncover new insights into the microvascular dysfunction that accelerates fibrotic diseases. Patients may benefit from findings that could lead to novel therapeutic strategies targeting these cellular processes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from fibrotic diseases, particularly those with conditions affecting the microvasculature.
Not a fit: Patients with acute injuries or conditions unrelated to fibrosis may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reverse fibrosis, improving patient outcomes.
How similar studies have performed: Other research has shown promising results in understanding the role of pericytes in fibrosis, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Gonzalez, Anjelica — Yale University
- Study coordinator: Gonzalez, Anjelica
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.